114
Participants
Start Date
May 1, 2005
Primary Completion Date
September 13, 2006
Study Completion Date
September 13, 2007
Repertaxin
An initial 'loading dose' of repertaxin was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The study medication was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
Placebo
An initial 'loading dose' of placebo was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The placebo was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
Duke University Medical Center, Durham
The Cleveland Clinic Foundation, Cleveland
Washington University School of Medicine, St Louis
University of Colorado, Health Sciences Centre, Denver
University of South California, Department of Cardiothoracic Surgery, Los Angeles
Toronto General Hospital, Toronto
Dompé Farmaceutici S.p.A
INDUSTRY